GB0609178D0 - Novel compounds - Google Patents

Novel compounds

Info

Publication number
GB0609178D0
GB0609178D0 GBGB0609178.9A GB0609178A GB0609178D0 GB 0609178 D0 GB0609178 D0 GB 0609178D0 GB 0609178 A GB0609178 A GB 0609178A GB 0609178 D0 GB0609178 D0 GB 0609178D0
Authority
GB
United Kingdom
Prior art keywords
alkyl
neutral
amino acid
compound
acid moiety
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0609178.9A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rega Foundation
University College Cardiff Consultants Ltd
Cardiff University
Original Assignee
Rega Foundation
University College Cardiff Consultants Ltd
Cardiff University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rega Foundation, University College Cardiff Consultants Ltd, Cardiff University filed Critical Rega Foundation
Priority to GBGB0609178.9A priority Critical patent/GB0609178D0/en
Publication of GB0609178D0 publication Critical patent/GB0609178D0/en
Priority to NZ573377A priority patent/NZ573377A/en
Priority to PCT/GB2007/001677 priority patent/WO2007129083A1/en
Priority to AU2007246814A priority patent/AU2007246814B2/en
Priority to DE602007014030T priority patent/DE602007014030D1/de
Priority to ES07732706T priority patent/ES2365057T3/es
Priority to AT07732706T priority patent/ATE506367T1/de
Priority to JP2009508479A priority patent/JP5261374B2/ja
Priority to BRPI0711354-4A priority patent/BRPI0711354A2/pt
Priority to PT07732706T priority patent/PT2016081E/pt
Priority to DK07732706.2T priority patent/DK2016081T3/da
Priority to SI200730661T priority patent/SI2016081T1/sl
Priority to CN2007800169982A priority patent/CN101443332B/zh
Priority to PL07732706T priority patent/PL2016081T3/pl
Priority to EA200870505A priority patent/EA015178B1/ru
Priority to TW096116477A priority patent/TWI385172B/zh
Priority to CA 2656780 priority patent/CA2656780C/en
Priority to KR1020087029280A priority patent/KR101447522B1/ko
Priority to EP07732706A priority patent/EP2016081B1/en
Priority to US12/226,044 priority patent/US8329664B2/en
Priority to IL194806A priority patent/IL194806A/en
Priority to CY20111100693T priority patent/CY1111711T1/el
Priority to US13/690,794 priority patent/US8859512B2/en
Priority to US14/482,125 priority patent/US9427447B2/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
GBGB0609178.9A 2006-05-09 2006-05-09 Novel compounds Ceased GB0609178D0 (en)

Priority Applications (24)

Application Number Priority Date Filing Date Title
GBGB0609178.9A GB0609178D0 (en) 2006-05-09 2006-05-09 Novel compounds
US12/226,044 US8329664B2 (en) 2006-05-09 2007-05-09 Anti-viral pyrimidine nucleoside derivatives
DK07732706.2T DK2016081T3 (da) 2006-05-09 2007-05-09 Antivirale pyrimidinnukleosidderivater, antivirale pyrimidinnukleosidderivater
CN2007800169982A CN101443332B (zh) 2006-05-09 2007-05-09 抗病毒嘧啶核苷衍生物
AU2007246814A AU2007246814B2 (en) 2006-05-09 2007-05-09 Anti-viral pyrimidine nucleoside derivatives
DE602007014030T DE602007014030D1 (de) 2006-05-09 2007-05-09 Antivirale pyrimidinnukleosidderivate
ES07732706T ES2365057T3 (es) 2006-05-09 2007-05-09 Derivados de nucleósidos de pirimidina antivíricos.
AT07732706T ATE506367T1 (de) 2006-05-09 2007-05-09 Antivirale pyrimidinnukleosidderivate
JP2009508479A JP5261374B2 (ja) 2006-05-09 2007-05-09 抗ウイルス性ピリミジンヌクレオシド誘導体
BRPI0711354-4A BRPI0711354A2 (pt) 2006-05-09 2007-05-09 composto método de sintetizar um composto, uso de um composto, método de profilaxia ou tratamento de infecção viral, e, composição farmacêutica
PT07732706T PT2016081E (pt) 2006-05-09 2007-05-09 Derivados de nucleósidos de pirimidina anti-virais
NZ573377A NZ573377A (en) 2006-05-09 2007-05-09 Anti-viral pyrimidine nucleoside derivatives
SI200730661T SI2016081T1 (sl) 2006-05-09 2007-05-09 Antivirusni pirimidinski nukleozidni derivati
PCT/GB2007/001677 WO2007129083A1 (en) 2006-05-09 2007-05-09 Anti-viral pyrimidine nucleoside derivatives
PL07732706T PL2016081T3 (pl) 2006-05-09 2007-05-09 Przeciwwirusowe pochodne pirymidynonukleozydów
EA200870505A EA015178B1 (ru) 2006-05-09 2007-05-09 Противовирусные производные пиримидиновых нуклеозидов
TW096116477A TWI385172B (zh) 2006-05-09 2007-05-09 新穎化合物
CA 2656780 CA2656780C (en) 2006-05-09 2007-05-09 Anti-viral pyrimidine nucleoside derivatives
KR1020087029280A KR101447522B1 (ko) 2006-05-09 2007-05-09 항바이러스성 피리미딘 뉴클레오시드 유도체
EP07732706A EP2016081B1 (en) 2006-05-09 2007-05-09 Anti-viral pyrimidine nucleoside derivatives
IL194806A IL194806A (en) 2006-05-09 2008-10-22 Porn History [d – 2,3] Pyrimidine Nucleoside, a Method for Preparation, Their Uses, and Pharmaceutical Preparations Containing Them
CY20111100693T CY1111711T1 (el) 2006-05-09 2011-07-15 Αντι-ιικα πυριμιδινικα νουκλεοζιτικα παραγωγα
US13/690,794 US8859512B2 (en) 2006-05-09 2012-11-30 Anti-viral pyrimidine nucleoside derivatives
US14/482,125 US9427447B2 (en) 2006-05-09 2014-09-10 Anti-viral pyrimidine nucleoside derivatives

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0609178.9A GB0609178D0 (en) 2006-05-09 2006-05-09 Novel compounds

Publications (1)

Publication Number Publication Date
GB0609178D0 true GB0609178D0 (en) 2006-06-21

Family

ID=36637171

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0609178.9A Ceased GB0609178D0 (en) 2006-05-09 2006-05-09 Novel compounds

Country Status (22)

Country Link
US (3) US8329664B2 (https=)
EP (1) EP2016081B1 (https=)
JP (1) JP5261374B2 (https=)
KR (1) KR101447522B1 (https=)
CN (1) CN101443332B (https=)
AT (1) ATE506367T1 (https=)
AU (1) AU2007246814B2 (https=)
BR (1) BRPI0711354A2 (https=)
CA (1) CA2656780C (https=)
CY (1) CY1111711T1 (https=)
DE (1) DE602007014030D1 (https=)
DK (1) DK2016081T3 (https=)
EA (1) EA015178B1 (https=)
ES (1) ES2365057T3 (https=)
GB (1) GB0609178D0 (https=)
IL (1) IL194806A (https=)
NZ (1) NZ573377A (https=)
PL (1) PL2016081T3 (https=)
PT (1) PT2016081E (https=)
SI (1) SI2016081T1 (https=)
TW (1) TWI385172B (https=)
WO (1) WO2007129083A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0009486D0 (en) * 2000-04-17 2000-06-07 Univ Cardiff Chemical compounds
GB2452556A (en) * 2007-09-07 2009-03-11 Univ Leuven Kath Nucleoside analogues esterified at 3 and/or 5 positions by neutral non-polar amino acid, or oligopeptide thereof, for combating Varicella Zoster virus
US9260469B2 (en) * 2010-10-09 2016-02-16 Contravir Pharmaceuticals, Inc. Method of preparation of antiviral compounds and useful intermediates thereof
CN102443032B (zh) * 2010-10-09 2015-07-22 英希比泰克斯公司 制备抗病毒组合物的方法及其中间体的应用
MD4110C1 (ro) * 2010-10-21 2011-12-31 Валериу РУДИК Preparat antiherpetiс
KR101875997B1 (ko) * 2015-05-04 2018-07-06 엔 앤드 엔 파마세우티칼스 인크. 엔-메탄노카르바티미딘을 이용한 대상포진의 치료방법

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62255499A (ja) 1986-04-28 1987-11-07 Teijin Ltd 螢光性ヌクレオシド又はヌクレオチド
EP0346108A3 (en) 1988-06-09 1991-04-24 The Wellcome Foundation Limited Anti-infective nucleosides
YU43193A (sh) 1992-06-22 1997-01-08 Eli Lilly And Company 2'-deoksi-2',2'-difluoro(4-supstituisani)pirimidinski nukleozidi antivirusnog i antikancerogenog dejstva i međuproizvodi
GB9505025D0 (en) 1995-03-13 1995-05-03 Medical Res Council Chemical compounds
US6022876A (en) 1996-11-15 2000-02-08 Yale University L-β-dioxolane uridine analogs and methods for treating and preventing Epstein-Barr virus infections
GB9708611D0 (en) 1997-04-28 1997-06-18 Univ Cardiff Chemical compounds
GB9716231D0 (en) 1997-07-31 1997-10-08 Amersham Int Ltd Base analogues
HK1053126A1 (zh) 1999-07-22 2003-10-10 新生物生物公司 酶催化的治疗活化
BR0012676A (pt) 1999-07-22 2003-07-01 Newbiotics Inc Métodos para tratamento de tumores resistentes a terapia
MXPA02000761A (es) 1999-07-22 2002-08-12 Newbiotics Inc Agentes terapeuticos anti-infecciosos catalizados por enzima.
GB0009486D0 (en) * 2000-04-17 2000-06-07 Univ Cardiff Chemical compounds
GB0011203D0 (en) * 2000-05-09 2000-06-28 Univ Cardiff Chemical compounds
US6875751B2 (en) * 2000-06-15 2005-04-05 Idenix Pharmaceuticals, Inc. 3′-prodrugs of 2′-deoxy-β-L-nucleosides
MY141594A (en) * 2000-06-15 2010-05-14 Novirio Pharmaceuticals Ltd 3'-PRODRUGS OF 2'-DEOXY-ß-L-NUCLEOSIDES
TW200500375A (en) * 2002-06-28 2005-01-01 Idenix Cayman Ltd Modified 2' and 3'-nucleoside prodrugs for treating flaviviridae
WO2004084453A2 (en) 2003-03-20 2004-09-30 Microbiologica Quimica E Farmaceutica Ltd. METHODS OF MANUFACTURE OF 2'-DEOXY-β-L-NUCLEOSIDES
US20050137141A1 (en) 2003-10-24 2005-06-23 John Hilfinger Prodrug composition
CA2566541C (en) 2004-06-07 2012-10-09 Anadys Pharmaceuticals, Inc. 3-.beta.-d-ribofuranosylthiazolo[4,5-d]pyrimidine nucleosides and uses thereof

Also Published As

Publication number Publication date
CY1111711T1 (el) 2015-10-07
KR101447522B1 (ko) 2014-10-06
US20100222295A1 (en) 2010-09-02
EA200870505A1 (ru) 2009-04-28
PL2016081T3 (pl) 2011-12-30
KR20090042204A (ko) 2009-04-29
EP2016081A1 (en) 2009-01-21
JP5261374B2 (ja) 2013-08-14
ATE506367T1 (de) 2011-05-15
CN101443332B (zh) 2011-11-09
ES2365057T3 (es) 2011-09-21
DK2016081T3 (da) 2011-06-20
IL194806A (en) 2015-08-31
EP2016081B1 (en) 2011-04-20
CA2656780C (en) 2015-04-28
NZ573377A (en) 2011-03-31
US20130096079A1 (en) 2013-04-18
US8859512B2 (en) 2014-10-14
US8329664B2 (en) 2012-12-11
CN101443332A (zh) 2009-05-27
WO2007129083A1 (en) 2007-11-15
AU2007246814B2 (en) 2012-07-19
US20150072948A1 (en) 2015-03-12
CA2656780A1 (en) 2007-11-15
JP2009536188A (ja) 2009-10-08
BRPI0711354A2 (pt) 2011-09-27
TWI385172B (zh) 2013-02-11
AU2007246814A1 (en) 2007-11-15
TW200813066A (en) 2008-03-16
SI2016081T1 (sl) 2011-09-30
US9427447B2 (en) 2016-08-30
DE602007014030D1 (de) 2011-06-01
IL194806A0 (en) 2009-09-22
EA015178B1 (ru) 2011-06-30
PT2016081E (pt) 2011-06-28

Similar Documents

Publication Publication Date Title
CY1111711T1 (el) Αντι-ιικα πυριμιδινικα νουκλεοζιτικα παραγωγα
EA201070164A1 (ru) Твердый препарат, включающий алоглиптин и гидрохлорид метформина
TW200730540A (en) Novel peptide compounds
TW200635585A (en) Monocyclic substituted methanones
JO3067B1 (ar) بيرميدينات بيرازولو امينو كمثبطات ل fak
TN2009000034A1 (en) Smac peptidomimetics useful as iap inhibitors
AR059349A1 (es) Sal especifica, forma hidratada y cristalina de un derivado de dihidropteridiona
EA200801287A1 (ru) Пиримидиновые производные для лечения аномального клеточного роста
IL194057A0 (en) Pyrimidine, quinazoline, pteridine and triazine derivatives
MX2009011579A (es) Pirimidinonas como moduladores de caseina cinasa ii (ck2).
EA201270275A1 (ru) Кристаллическое соединение пиридазина
NO20075270L (no) Antibakterielle amid-makrocykler V
WO2006116733A3 (en) Protein kinase inhibitors
JP2009536188A5 (https=)
SI2850054T1 (en) A process for the production of amino acid compounds
GB0717526D0 (en) Improvements in or relating to compositions for the treatment or prophylaxis of viral infections
ATE485291T1 (de) Imidazolidinonylaminopyrimidinverbindungen zur behandlung von krebs
IL195657A0 (en) Pseudo proline dipeptides
WO2007068417A3 (en) Process for the preparation of amines
EA200702637A1 (ru) Производные пурина
DE60203890D1 (de) Apfelsäureadditionssalze von terbinafin
TW200635911A (en) Sulfanyl substituted phenyl methanones
JO3270B1 (ar) مشتقات كوينولين بصفة عوامل مضادة للبكتيريا
RU2006125090A (ru) Противовоспалительное средство для наружного применения
DE602006005488D1 (de) Verfahren zur herstellung von losartanderivaten durch chlorierung und reduktion der entsprechenden 1h-imidazol-5-carbaldehyde

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)